VYNE Therapeutics (NASDAQ:VYNE) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

VYNE Therapeutics (NASDAQ:VYNE) released its quarterly earnings results on Thursday. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02, Zacks reports. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 75.03%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million.

VYNE Therapeutics Stock Down 0.3%

VYNE stock traded down $0.00 during midday trading on Friday, reaching $0.35. The company’s stock had a trading volume of 3,204,479 shares, compared to its average volume of 1,903,457. The business’s 50-day simple moving average is $0.34 and its 200-day simple moving average is $0.79. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $4.30. The stock has a market cap of $8.97 million, a PE ratio of -0.45 and a beta of 1.95.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in VYNE. Boothbay Fund Management LLC bought a new stake in VYNE Therapeutics in the second quarter valued at about $176,000. Jane Street Group LLC bought a new position in VYNE Therapeutics during the second quarter worth about $206,000. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of VYNE Therapeutics by 87.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after buying an additional 300,000 shares during the period. 83.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. HC Wainwright lowered shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Lifesci Capital lowered shares of VYNE Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 30th. Finally, BTIG Research cut shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 31st. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $6.25.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.